These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 29481941)

  • 1. The Role of Interleukins and Inflammatory Markers in the Early Restenosis of Covered Stents in the Femoropopliteal Arterial Segment.
    Guimaraes TS; da Rocha LA; Becari C; Piccinato CE; Joviliano RD; Ribeiro MS; Joviliano EE
    Ann Vasc Surg; 2018 Jul; 50():88-95. PubMed ID: 29481941
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interleukins and inflammatory markers in in-stent restenosis after femoral percutaneous transluminal angioplasty.
    Araújo PV; Ribeiro MS; Dalio MB; Rocha LA; Viaro F; Dellalibera Joviliano R; Piccinato CE; Évora PR; Joviliano EE
    Ann Vasc Surg; 2015; 29(4):731-7. PubMed ID: 25725274
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of the kallikrein-kinin system, matrix metalloproteinases, and tissue inhibitors of metalloproteinases in the early restenosis of covered stents in the femoropopliteal arterial segment.
    Rocha LA; Piccinato CE; Ribiero MS; Becari C; Joviliano RD; Joviliano EE
    J Vasc Surg; 2017 Jan; 65(1):119-127. PubMed ID: 27667150
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of the kallikrein-kinin system, metalloproteinases, and their tissue inhibitors in the in-stent restenosis after peripheral percutaneous angioplasty.
    Ribeiro MS; Dellalibera-Joviliano R; Becari C; Teixeira FR; Araujo PV; Piccinato CE; Campos CP; Evora PR; Joviliano EE
    Ann Vasc Surg; 2014 May; 28(4):1005-15. PubMed ID: 24440188
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drug-Eluting Stent vs Percutaneous Transluminal Angioplasty for Treatment of Femoropopliteal In-Stent Restenosis: Results From a Retrospective 1-Year Multicenter Study.
    Murata N; Takahara M; Soga Y; Nakano M; Yamauchi Y; Zen K; Kawasaki D; Yokoi H; Tosaka A; Tanaka N; Iida O
    J Endovasc Ther; 2016 Aug; 23(4):642-7. PubMed ID: 27099284
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Paclitaxel-Eluting Balloon Versus Standard Balloon Angioplasty in In-Stent Restenosis of the Superficial Femoral and Proximal Popliteal Artery: 1-Year Results of the PACUBA Trial.
    Kinstner CM; Lammer J; Willfort-Ehringer A; Matzek W; Gschwandtner M; Javor D; Funovics M; Schoder M; Koppensteiner R; Loewe C; Ristl R; Wolf F
    JACC Cardiovasc Interv; 2016 Jul; 9(13):1386-92. PubMed ID: 27388828
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of Drug-Eluting Stent Implantation for Femoropopliteal In-Stent Occlusion.
    Tomoi Y; Soga Y; Iida O; Shiraki T; Kobayashi Y; Hiramori S; Ando K
    J Endovasc Ther; 2016 Jun; 23(3):461-7. PubMed ID: 27004496
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Incidence and the clinical impact of stent fractures after primary stenting for TASC C and D femoropopliteal lesions at 1 year.
    Davaine JM; Quérat J; Guyomarch B; Brennan MÁ; Costargent A; Chaillou P; Patra P; Gouëffic Y
    Eur J Vasc Endovasc Surg; 2013 Aug; 46(2):201-12. PubMed ID: 23773773
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Six-month results of stenting of the femoropopliteal artery and predictive value of interleukin-6: Comparison with high-sensitivity C-reactive protein.
    Guo S; Zhang Z; Wang L; Yuan L; Bao J; Zhou J; Jing Z
    Vascular; 2020 Dec; 28(6):715-721. PubMed ID: 32408853
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High dose-rate brachytherapy for the treatment of lower extremity in-stent restenosis.
    Ho KJ; Devlin PM; Madenci AL; Semel ME; Gravereaux EC; Nguyen LL; Belkin M; Menard MT
    J Vasc Surg; 2017 Mar; 65(3):734-743. PubMed ID: 27986482
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In Vivo Quantification of the Deformations of the Femoropopliteal Segment: Percutaneous Transluminal Angioplasty vs Nitinol Stent Placement.
    Gökgöl C; Schumann S; Diehm N; Zheng G; Büchler P
    J Endovasc Ther; 2017 Feb; 24(1):27-34. PubMed ID: 28095767
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of Endovascular Versus Bypass Surgery in Femoropopliteal TASC II D Lesions: A Single-Center Study.
    Veraldi GF; Mezzetto L; Macrì M; Criscenti P; Corvasce A; Poli R
    Ann Vasc Surg; 2018 Feb; 47():179-187. PubMed ID: 28943491
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intravascular Ultrasound-Derived Stent Dimensions as Predictors of Angiographic Restenosis Following Nitinol Stent Implantation in the Superficial Femoral Artery.
    Miki K; Fujii K; Kawasaki D; Shibuya M; Fukunaga M; Imanaka T; Tamaru H; Sumiyoshi A; Nishimura M; Horimatsu T; Saita T; Okada K; Kimura T; Honda Y; Fitzgerald PJ; Masuyama T; Ishihara M
    J Endovasc Ther; 2016 Jun; 23(3):424-32. PubMed ID: 27044270
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intravascular ultrasound measurements after drug-eluting stent placement in femoropopliteal lesions: determining predictors of restenosis.
    Mori S; Hirano K; Nakano M; Muramatsu T; Tsukahara R; Ito Y; Ishimori H
    J Endovasc Ther; 2015 Jun; 22(3):341-9. PubMed ID: 25862363
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preoperative inflammatory status as a predictor of primary patency after femoropopliteal stent implantation.
    Nakazawa KR; Wengerter SP; Power JR; Lookstein RA; Tadros RO; Ting W; Faries PL; Vouyouka AG
    J Vasc Surg; 2017 Jul; 66(1):151-159. PubMed ID: 28259571
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical outcomes of balloon angioplasty alone versus nitinol stent implantation in patients with small femoropopliteal artery disease: Observations from the Retrospective Multicenter Analysis for Femoropopliteal Stenting (REAL-FP).
    Kamioka N; Soga Y; Kuramitsu S; Iida O; Hirano K; Suzuki K; Kawasaki D; Yamaoka T; Suematsu N; Shintani Y; Miyashita Y; Takahashi H; Tsuchiya T; Shinozaki N; Okazaki S; Ando K
    Catheter Cardiovasc Interv; 2017 Nov; 90(5):790-797. PubMed ID: 28722294
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Paclitaxel-Eluting Balloon vs Standard Angioplasty to Reduce Restenosis in Diabetic Patients With In-Stent Restenosis of the Superficial Femoral and Proximal Popliteal Arteries: Three-Year Results of the DEBATE-ISR Study.
    Grotti S; Liistro F; Angioli P; Ducci K; Falsini G; Porto I; Ricci L; Ventoruzzo G; Turini F; Bellandi G; Bolognese L
    J Endovasc Ther; 2016 Feb; 23(1):52-7. PubMed ID: 26511896
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictors of restenosis in the use of helical interwoven nitinol stents to treat femoropopliteal occlusive disease.
    Chan YC; Cheng SW; Cheung GC
    J Vasc Surg; 2015 Nov; 62(5):1201-9. PubMed ID: 26169015
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SUMMIT registry: one-year outcomes after implantation of the EPIC self-expanding nitinol stent in the femoropopliteal segment.
    Werner M; Piorkowski M; Thieme M; Nanning T; Beschorner U; Rastan A; Zeller T; Scheinert D
    J Endovasc Ther; 2013 Dec; 20(6):759-66. PubMed ID: 24325691
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Meta-Analysis-Derived Benchmarks of Patency and Target Lesion Revascularization of Percutaneous Balloon Angioplasty from Prospective Clinical Trials of Symptomatic Femoropopliteal In-Stent Restenosis.
    Shammas NW; Jones-Miller S; Lemke J
    J Vasc Interv Radiol; 2016 Aug; 27(8):1195-203. PubMed ID: 27350033
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.